Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma

Source: OncLive, June 2020

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we passed the mic to Jason J. Luke, MD, FACP, and Diwakar Davar, MD, to discuss the clinical trials that have shaped the past, present, and potential future of neoadjuvant versus adjuvant therapy for patients with melanoma.

Historically, adjuvant therapy has been a standard of care for patients with melanoma. Despite the benefit in relapse-free survival that adjuvant therapies confer, neoadjuvant therapy has started to pique interest in the field. The belief is that patients may have a more robust immune microenvironment up front, and thus, may be more responsive to neoadjuvant therapy. However, treatment selection and potential toxicities that could prevent surgical candidacy remain key concerns in this area.

READ THE ORIGINAL FULL ARTICLE